FDA issues warning letter over Yaz DTC ads

The FDA has issued a warning letter to Bayer for two commercials, "Not Gonna Take It" and "Balloons," for its birth control pill, Yaz. According to the FDA, the commercials overstate the efficacy of the pill, minimize its risks and broadens the pills indication by falsely suggesting that Yaz has been approved for treating pre-menstrual syndrome.

The Yaz label warns patients that the contraceptive has not been evaluated to treat premenstrual syndrome, but the FDA notes that this is not mentioned in the "Not Gonna Take It" commercial. Yaz is in fact approved for treating "moderate acne vulgarities," as well as premenstrual dysphoric disorder (PMDD)--a more severe condition that causes disruptive emotional and physical symptoms, including depression, anxiety, persistent anger, headaches and joint pain. But, according to the warning letter, not only does the commercial suggest  that Yaz's is able to treat acne of all severities, in touting the benefits of Yaz in treating such common symptoms as "irritability" and "moodiness," the commercial fails to distinguish between PMS and the more serious PMDD, leading viewers to believe that Yaz is effective at treating PMS.

The FDA also warns Bayer about a second commercial, "Balloons (video)," in which the song "Goodbye to You" plays in the background as women release balloons displaying their symptoms into the air. The agency says the ad misleads viewers to believe that Yaz can completely cure patients of their symptoms.

- check out the "Balloons" commercial
- view the FDA warning letter (.pdf)
- view the FDA story board of "Not Gonna Take It" (.pdf)

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.